Other Anti-Microbial Markets
The Company will continue to explore new opportunities with or without partners to develop new research projects that have the potential to deliver new drugs meeting clear clinical and commercial criteria. There is a wide range of indications where effective new anti-infective treatments are needed that address the global threat of AMR and Destiny Pharma welcomes discussion with interested parties on possible new projects.
Respiratory infection prevention
The properties of XF-73 could be extended into the area for the prevention of staphylococcal respiratory infections such as hospital and ventilator associated pneumonia (HVAP), where there is a growing understanding of the role of Staphylococcus aureus carriage and lung infections.
Other respiratory treatment opportunities are available to pursue for XF drugs including inhaled product for the treatment of antibiotic resistant strains of Gram positive pathogens, including those where biofilm involvement may exacerbate the infection.
XF Drugs have demonstrated activity against staphylococci within formed biofilms. This is a potentially advantageous feature as many antibiotics cannot act against such bacteria within biofilms.
Bacterial biofilms are implicated in chronic and recurring infection and there is a growing understanding of their role and the value in developing strategies/products which can address this issue in tissue and medical device related infections. For example, bacterial biofilm is implicated in chronic lung infection in conditions such as cystic fibrosis where Staphylococcus aureus, including MRSA and Pseudomonas aeruginosa are the most common pathogens in this condition.
The Company was granted its US Biofilm patent in May 2016 having already obtained grant in the EU and will continue to develop products in this exciting new area.